

UNITED STAT.

DEPARTMENT OF COMMERCE

Patent and Tre mark Office

Address: COMMIL WINER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

 APPLICATION NO.
 FILING DATE
 FIRST NAMED INVENTOR
 ATTORNEY DOCKET NO.

 09/491,063
 01/25/00
 POLSTON
 J
 UF-232XC1

023557 HM12/1002 SALIWANCHIK LLOYD & SALIWANCHIK A PROFESSIONAL ASSOCIATION 2421 N.W. 41ST STREET SUITE A-1 GAINESVILLE FL 32606-6669

ART UNIT PAPER NUMBER

EXAMINER

1635 DATE MAILED:

10/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No.	Applicant(s)
Office Action Summary	Аррисацоп но.	
	09/491,063	POLSTON ET AL.
	Examiner	Art Unit
	Mary Schmidt	1635
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory peri - Failure to reply within the set or extended period for reply will, by sta - Any reply received by the Office later than three months after the ma earmed patent term adjustment. See 37 CFR 1.704(b). Status	N. 1.136 (a). In no event, however, may a a reply within the statutory minimum of thirt od will apply and will expire SIX (6) MON tute, cause the application to become AB	reply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on _	·	
2a) This action is FINAL . 2b) ⊠	This action is non-final.	•
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4)⊠ Claim(s) <u>1-18</u> is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-18</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claims are subject to restriction and	d/or election requirement.	
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are objected to by the Examiner.		
11) The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. § 119		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).		
a) All b) Some * c) None of:		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the paper application from the International * See the attached detailed Office action for a 	Bureau (PCT Rule 17.2(a)).	
14) Acknowledgement is made of a claim for do		
		KATRINA TURNER PATENT ANALYST
Attachment(s)	18) Intervie	w Summary (PTO-413) Paper No(s)
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper Note 	3) 19) Notice of	of Informal Patent Application (PTO-152)

沙

Application/Control Number: 09/491,063

Art Unit: 1635

DETAILED ACTION

Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
 - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 1-14 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for expressing known Rep proteins in certain plant species, does not reasonably provide enablement for expressing any Rep protein, fragment or variant thereof, in any species of plant as broadly claimed for the methods claimed for increased resistance to infection of the plants. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claim 1 is drawn to a method for providing resistance to infection by a plant virus in a plant or plant tissue via transforming the plant or tissue with a polynucleotide that encodes a Rep protein, fragment or variant thereof, of said plant virus. Claims 2-3 specify the virus as a geminivirus such as tomato mottle virus, cabbage leaf curl geminivirus, potato yellow mosaic virus, tomato golden mosaic virus, tomato yellow mosaic virus, tomato leaf crumple virus, tomato yellow leaf curl virus and pepper huasteco virus. Claims 4-5 specify the Rep protein is from tomato mottle geminivirus or tomato leaf curl virus (TYLCV-Is). Claim 6 specifies the plant or

Application/Control Number: 09/491,063

Art Unit: 1635

plant tissue is tomato or tobacco. Claims 7-8 specify that the plant or plant tissue is transformed by agroinfection or biolistic targeting. Claims 9-14 specify that the plant or plant tissue has increased resistance to infection by a plant virus, and encompasses hybrid plant. Claim 13 specifies that the plant is a seed.

In regards to the claims drawn to fragments or variants of the Rep encoding polynucleotides, there is a high level of unpredictability in the art for determining the functional capacity of any possible fragment or variant of a known protein. The problem of predicting protein structure from sequence data and in turn utilizing predicted structural determinations to ascertain functional aspects of the protein is extremely complex. While it is known that many amino acid substitutions are generally possible in any given protein the positions within the protein's sequence where such amino acid substitutions can be made with a reasonable expectation of success are limited. Certain positions in the sequence are critical to the protein's structure/function relationship, e.g. such as various sites or regions directly involved in binding, activity and in providing the correct three-dimensional spatial orientation of binding and active sites. These or other regions may also be critical determinants of antigenicity. These regions can tolerate only relatively conservative substitutions or no substitutions (see Wells, 1990, Biochemistry 29:8509-8517; Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495). However, Applicant has provided little or no guidance beyond the mere presentation of sequence data to enable one of ordinary skill in the art to determine, without undue experimentation, the positions in the protein which are tolerant to

Application/Control Number: 09/491,063

Art Unit: 1635

change (e.g. such as by amino acid substitutions or deletions), and the nature and extent of changes that can be made in these positions. For instance, art-recognized procedures for producing and screening for active muteins is not adequate guidance as to the nature of active derivatives that may be constructed, but is merely an invitation to the artisan to use the current invention as a starting point for further experimentation. Even if an active or binding site were identified in the specification, they may not be sufficient, as the ordinary artisan would immediately recognize that an active or binding site must assume the proper three-dimensional configuration to be active, which conformation is dependent upon surrounding residues; therefore substitution of non-essential residues can often destroy activity. The art recognizes that function cannot be predicted from structure alone (Bork, 2000, Genome Research 10:398-400; Skolnick et al., 2000, Trends in Biotech. 18(1):34-39, especially p. 36 at Box 2; Doerks et al., 1998, Trends in Genetics 14:248-250; Smith et al., 1997, Nature Biotechnology 15:1222-1223; Brenner, 1999, Trends in Genetics 15:132-133; Bork et al., 1996, Trends in Genetics 12:425-427). Due to the large quantity of experimentation necessary to generate the infinite number of derivatives recited in the claims and possibly screen same for activity, the lack of direction/guidance presented in the specification regarding which structural features are required in order to provide activity, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art which establishes the unpredictability of the effects of mutation on protein structure and function, and the breadth of the claims which fail to recite any structural or functional

Application/Control Number: 09/491,063

Art Unit: 1635

limitations, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

The assertion that the disclosed sequences have biological activities similar to any other possible isolated sequence having homology (ie. having fragments or variants), or which hybridizes to the disclosed sequences cannot be accepted in the absence of supporting evidence, because the relevant literature reports examples of polypeptide families wherein individual members have distinct, and sometimes even opposite, biological activities. For example, Tischer et al. (U.S. Patent 5,194,596) establishes that VEGF (a member of the PDGF, or platelet-derived growth factor, family) is mitogenic for vascular endothelial cells but not for vascular smooth muscle cells, which is opposite to the mitogenic activity of naturally occurring PDGF which is mitogenic for vascular smooth muscle cells but not for vascular endothelial cells (column 2, line 46 to column 3, line 2). The differences between PDGF and VEGF are also seen in vivo, wherein endothelial-pericyte associations in the eye are disrupted by intraocular administration of PDGF but accelerated by intraocular administration of VEGF (Benjamin et al., 1998, Development 125:1591-1598; see Abstract and pp. 1594-1596). In the transforming growth factor (TGF) family, Vukicevic et al. (1996, PNAS USA 93:9021-9026) disclose that OP-1, a member of the TGF-\(\beta\) family of proteins, has the ability to induce metanephrogenesis, whereas closely related TGF-β family members BMP-2 and TGF-β1 had no effect on metanephrogenesis under identical conditions (p. 9023, paragraph bridging columns 1-2). Similarly, PTH and PTHrP are two structurally closely related proteins which can have opposite effects on bone resorption (Pilbeam

Application/Control Number: 09/491,063

Art Unit: 1635

et al., 1993, Bone 14:717-720; see p. 717, second paragraph of Introduction). Finally, Kopchick et al. (U.S. Patent 5,350,836) disclose several antagonists of vertebrate growth hormone that differ from naturally occurring growth hormone by a single amino acid (column 2, lines 37-48).

Generally, the art acknowledges that function cannot be predicted based solely on structural similarity to a protein found in the sequence databases. For example, Skolnick et al. (2000, Trends in Biotech. 18:34-39) state that knowing the protein structure by itself is insufficient to annotate a number of functional classes, and is also insufficient for annotating the specific details of protein function (see Box 2, p. 36). Similarly, Bork (2000, Genome Research 10:398-400) states that the error rate of functional annotations in the sequence database is considerable, making it even more difficult to infer correct function from a structural comparison of a new sequence with a sequence database (see especially p. 399). Such concerns are also echoed by Doerks et al. (1998, Trends in Genetics 14:248-250) who state that (1) functional information is only partially annotated in the database, ignoring multi functionality, resulting in underpredictions of functionality of a new protein and (2) overpredictions of functionality occur because structural similarity often does not necessarily coincide with functional similarity. Smith et al. (1997, Nature Biotechnology 15:1222-1223) remark that there are numerous cases in which proteins having very different functions share structural similarity due to evolution from a common ancestral gene. Brenner (1999, Trends in Genetics 15:132-133) argues that accurate inference of function from homology must be a difficult problem since, assuming there are only about 1000 major gene superfamilies in nature, then most homologs must have different molecular

Application/Control Number: 09/491,063

Art Unit: 1635

and cellular functions. Finally, Bork et al. (1996, Trends in Genetics 12:425-427) add that the software robots that assign functions to new proteins often assign a function to a whole new protein based on structural similarity of a small domain of the new protein to a small domain of a known protein. Such questionable interpretations are written into the sequence database and are then considered facts.

Therefore, based on the discussions above concerning the specific examples of structurally similar proteins that have different functions, along with the art's recognition that one cannot rely upon structural similarity alone to determine functionality, the specification fails to teach the skilled artisan how to use the claimed scope of nucleic acids and polynucleotides to make biologically active Rep fragment or variant without resorting to undue experimentation to determine what the specific biological activities of the possible claimed sequences are.

Due to the large quantity of experimentation necessary to determine an activity or property of any sequence such that it can be determined how to use the claimed nucleic acids or polynucleotides encoding any Rep fragment or variant, the lack of direction/guidance presented in the specification regarding same, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art establishing that biological activity cannot be predicted based on structural similarity, and the breadth of the claims which fail to recite particular biological activities and also embrace a broad class of structural fragments and variants, undue experimentation would be required of the skilled artisan to make and/or use the claimed invention in its full scope.

Application/Control Number: 09/491,063 Page 8

Art Unit: 1635

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States. (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

4. Claims 1-3, 5-6, 9-10, 12, 15, 17 and 18 are rejected under 35 U.S.C. 102(b) as being anticipated by Brunetti et al. (Molecular Plant-Microbe Interactions 10 (5):p571-579, 1997; IDS Referece AP).

The claims are described above in the 35 U.S.C. 112 rejection.

Brunetti et al. are relied upon to teach expression of a truncated viral Rep protein in tomatos which confer resistance to tomato yellow leaf curl virus. They teach plants and plant cells transformed with a recombinant construct for expressing the Rep protein.

Brunetti et al. thus anticipate the claimed invention.

5. Claims 1-4, 6, 9-11, 15-16 and 18 are rejected under 35 U.S.C. 102(b) as being anticipated by Strout et al. (Phytopathology 87 (6 SUPPL.):pS94, 1997; IDS Reference AT).

The claims are described above in the 35 U.S.C. 112 rejection.

Application/Control Number: 09/491,063

Art Unit: 1635

Strout et al. are relied upon to teach expression of a Rep gene in tomatos which confer resistance to tomato mottle virus. They teach plants and plant cells transformed with a recombinant construct for expressing the Rep protein.

Stout et al. thus anticipate the claimed invention.

6. Claims 1-4, 6, 7-11, 15-16 and 18 are rejected under 35 U.S.C. 102(e) as being anticipated by Strout et al. (U.S. Patent 6,291,743 B2).

The claims are described above in the 35 U.S.C. 112 rejection.

Strout et al. are relied upon to teach expression of a Rep gene in tomatos which confer resistance to tomato mottle virus and TYLCV. They teach plants and plant cells transformed with a recombinant construct for expressing the Rep protein. They also teach general methods known in the art for plant transformation.

Stout et al. thus anticipate the claimed invention.

Application/Control Number: 09/491,063 Page 10

Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Mary M. Schmidt*, whose telephone number is (703) 308-4471.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *John LeGuyader*, may be reached at (703) 308-0447.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

ANDREWWANG PRIMARY EXAMINER